Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Brexpiprazole in Adults With Borderline Personality Disorder
NCT04186403Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jan 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of brexpiprazole in borderline personality disorder (BPD) (2 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events up to 16 weeks. Started Jan 2020; status: completed.
02
Drugs
brexpiprazole
03
Conditions
borderline personality disorder (BPD)
Beyond the preview
Go deeper on NCT04186403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04186403.